In November, I believed that shares of Globus Medical (NYSE:GMED) had seen a well deserved re-rating after a solid year. After acquiring NuVasive, the company delivered on three consecutive ...

Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...

The performance reflects the strong potential of the combined Globus-NuVasive organization and the growing value creation from the merger. Impressively, the company registered the highest ...

Globus Medical's results underscore a strong quarter, with effective execution of strategic initiatives, notably the full integration of the September 2023 NuVasive merger. Globus Medical offers ...

We have yet to fully harness the power of the combined Globus NuVasive product offering internationally and feel this will be a significant tailwind as we move forward in 2025 and beyond.

With the complementary strengths of Globus Medical engineering and NuVasive relations, education and training, GMED aims to outpace market growth, leading to accelerated EPS growth and an increase ...

These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive business and Globus Medical, Inc.’s ability to successfully ...

AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the ...

Globus Medical, Inc. GMED reported fourth-quarter ... Net sales improvement was driven by the addition of NuVasive, as well as increased volume of spine product sales and enabling technology ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...